KAI Pharmaceuticals Inks $13-Million Development Deal With Ono Pharmaceutical
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, recently announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI’s lead product candidate.
KAI-4169 is a novel therapeutic agent in Phase II clinical testing as an intravenous (IV) formulation for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). Under the terms of the agreement, Ono receives exclusive rights to all indications for injectable formulations of KAI-4169 in
KAI will receive approximately $13 million in an up-front payment from Ono, as well as significant development, regulatory, and commercialization milestones. KAI also will receive a royalty on sales. Additional financial terms of the agreement were not disclosed.
“This partnership with Ono is a critical event for the KAI-4169 program, allying us with a partner that has a strong track-record advancing innovative pharmaceutical products,” said Steven James, President and CEO of KAI. “We are excited about the continued momentum of the KAI-4169 program, and we anticipate completing the Phase II trial and reporting top-line data by the end of this year.”
“Ono’s research and development principle is to develop and deliver drugs that truly benefit patients and society. We put this into practice by tackling diseases that remain unconquered and addressing high unmet healthcare needs where patient satisfaction with current treatments is low. We believe KAI-4169 has the potential to satisfy these unmet needs and, therefore, fits Ono’s strategy very well. For example, a key differentiating advantage of KAI-4169 is that it is an IV formulation that is designed to improve drug adherence. We plan to develop KAI-4169 expeditiously in
Total Page Views: 1202
